Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer
暂无分享,去创建一个
P. Flamen | M. Paesmans | L. Ameye | T. Kamoun | A. Hendlisz | E. Woff | T. Guiot | C. Garcia | Erwin Woff
[1] Seung-Yong Jeong,et al. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[2] Jeffrey P Leal,et al. Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability , 2017, The Journal of Nuclear Medicine.
[3] G. Beretta,et al. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] G. Salles,et al. Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Tournigand,et al. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] P. Gaulard,et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] W. Oyen,et al. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer. , 2015, PET clinics.
[9] S. Krishnamoorthy,et al. Management of regorafenib-related toxicities: a review , 2015, Therapeutic advances in gastroenterology.
[10] K. Hirakawa,et al. The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer , 2015, BMC Cancer.
[11] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[12] P. Flamen,et al. Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol , 2015, BMJ Open.
[13] R. Wahl,et al. Two-time-point FDG PET/CT: liver SULmean repeatability. , 2015, AJR. American journal of roentgenology.
[14] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[15] D. Sargent,et al. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] H. Tilly,et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[17] T. Conroy,et al. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial , 2014, British Journal of Cancer.
[18] Takaaki Kobayashi,et al. Modified Glasgow prognostic score in patients with incurable stage IV colorectal cancer. , 2013, American journal of surgery.
[19] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[20] Marc Kachelriess,et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[22] Jacob Cohen. A Coefficient of Agreement for Nominal Scales , 1960 .
[23] B. Loo,et al. Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235 , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[24] A. Lièvre,et al. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[25] M. Piccart-Gebhart,et al. SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC). , 2014 .
[26] Peter Smeets,et al. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[27] Sumithra J. Mandrekar,et al. Finding Optimal Cutpoints for Continuous Covariates with Binary and Time-to-Event Outcomes , 2006 .